6 मिलीग्राम पेगसाइट इंजेक्शन

उत्पाद वर्णन

Pegfilgrastim is a medication used to reduce the risk of infection in patients undergoing cancer chemotherapy. It belongs to a class of drugs known as granulocyte colony-stimulating factors (G-CSFs). Pegfilgrastim is a longer-acting form of filgrastim, which stimulates the production of white blood cells (neutrophils) in the bone marrow, helping to prevent infections in patients undergoing chemotherapy. Here's some information about pegfilgrastim:

1. Indication Pegfilgrastim injection is indicated to decrease the incidence of infection as manifested by febrile neutropenia (low white blood cell count with fever) in patients receiving myelosuppressive chemotherapy associated with a significant risk of febrile neutropenia.

2. Mechanism of Action Pegfilgrastim works by stimulating the bone marrow to produce more neutrophils, which are a type of white blood cell important for fighting infections. It does this by binding to and activating specific receptors on the surface of cells in the bone marrow, stimulating the production and release of neutrophils into the bloodstream.

3. Dosage Pegfilgrastim is administered as a subcutaneous injection (under the skin) typically 24 to 72 hours after completion of chemotherapy. The recommended dose is usually 6 mg per chemotherapy cycle. It is provided in a prefilled syringe or autoinjector for ease of administration.

4. Side Effects Common side effects of pegfilgrastim injection may include bone pain, musculoskeletal pain, headache, fatigue, and injection site reactions (such as redness, swelling, or bruising at the injection site). Less common but potentially serious side effects may include allergic reactions, spleen rupture, acute respiratory distress syndrome, and others.

5. Monitoring Patients receiving pegfilgrastim injection should be monitored for any signs of adverse reactions or complications. Blood counts may be monitored regularly to assess neutrophil levels and to adjust the dosage if necessary.

6. Precautions and Contraindications Pegfilgrastim injection should be used with caution in patients with a history of allergic reactions to pegfilgrastim or filgrastim, latex allergies, or sickle cell disorders. It is not recommended for use in patients with a history of splenectomy (spleen removal) or in patients with acute myeloid leukemia.

Pegfilgrastim injection is an important supportive therapy for patients undergoing chemotherapy to reduce the risk of infection. Its use should be guided by a healthcare professional experienced in the management of chemotherapy-induced neutropenia. As with any medication, it's essential to discuss the potential benefits and risks of pegfilgrastim injection with a healthcare provider before starting treatment.

Key Benefits of Pegfilgrastim Injection

Pegfilgrastim PEG GCFS Injection enhances the bodys immune response during chemotherapy by stimulating neutrophil production, thereby lowering the risk of infections. It allows patients to maintain their chemotherapy schedules without delays caused by neutropenia, improving overall treatment outcomes and promoting faster recovery.


Usage and Administration Guidelines

This injection should only be administered under the supervision or recommendation of a qualified physician. The standard dose is 6 mg, delivered as a single subcutaneous injection, with the exact timing and frequency tailored to the patients specific treatment plan. Always adhere strictly to your healthcare providers instructions for safe and effective use.


Safe Storage Instructions

To maintain the stability and potency of Pegfilgrastim PEG GCFS Injection, store it in a dry and cool place, avoiding direct sunlight and exposure to high temperatures. Adhering to recommended storage conditions is essential for preserving the efficacy of the medication until administration.